Condition
Advanced Solid Tumors
Estimated Enrollment: 60
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: OSI-930-103
Study First Received: December 26, 2007
Last Updated: September 26, 2011
Estimated Primary Completion Date: April 2010
Primary Outcome Measures:
Determine the maximum tolerated dose (MTD), evaluate the pharmacokinetic profiles|Safety, evaluate pharmacodynamic relationships
Sponsors and Collaborators:
Astellas Pharma Inc|OSI Pharmaceuticals
Website Link: https://ClinicalTrials.gov/show/NCT00603356
